356 related articles for article (PubMed ID: 21544811)
21. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.
Tang X; Kadara H; Behrens C; Liu DD; Xiao Y; Rice D; Gazdar AF; Fujimoto J; Moran C; Varella-Garcia M; Lee JJ; Hong WK; Wistuba II
Clin Cancer Res; 2011 Apr; 17(8):2434-43. PubMed ID: 21257719
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].
Han C; Zou H; Ma J; Zhou Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):882-91. PubMed ID: 20840818
[TBL] [Abstract][Full Text] [Related]
23. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
24. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
[TBL] [Abstract][Full Text] [Related]
25. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
26. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.
Sun L; Zhang Q; Luan H; Zhan Z; Wang C; Sun B
J Exp Clin Cancer Res; 2011 Mar; 30(1):30. PubMed ID: 21414214
[TBL] [Abstract][Full Text] [Related]
27. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
[TBL] [Abstract][Full Text] [Related]
28. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.
Stella GM; Scabini R; Inghilleri S; Cemmi F; Corso S; Pozzi E; Morbini P; Valentini A; Dore R; Ferrari S; Luisetti M; Zorzetto M
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1327-35. PubMed ID: 23644698
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
30. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
31. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
32. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
33. E2F1-mediated repression of WNT5A expression promotes brain metastasis dependent on the ERK1/2 pathway in EGFR-mutant non-small cell lung cancer.
Li H; Tong F; Meng R; Peng L; Wang J; Zhang R; Dong X
Cell Mol Life Sci; 2021 Mar; 78(6):2877-2891. PubMed ID: 33078208
[TBL] [Abstract][Full Text] [Related]
34. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
35. Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis.
Sun H; Chung WC; Ryu SH; Ju Z; Tran HT; Kim E; Kurie JM; Koo JS
Cancer Prev Res (Phila); 2008 Oct; 1(5):316-28. PubMed ID: 19138976
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
Kim WY; Prudkin L; Feng L; Kim ES; Hennessy B; Lee JS; Lee JJ; Glisson B; Lippman SM; Wistuba II; Hong WK; Lee HY
Cancer; 2012 Aug; 118(16):3993-4003. PubMed ID: 22359227
[TBL] [Abstract][Full Text] [Related]
37. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Ihle NT; Byers LA; Kim ES; Saintigny P; Lee JJ; Blumenschein GR; Tsao A; Liu S; Larsen JE; Wang J; Diao L; Coombes KR; Chen L; Zhang S; Abdelmelek MF; Tang X; Papadimitrakopoulou V; Minna JD; Lippman SM; Hong WK; Herbst RS; Wistuba II; Heymach JV; Powis G
J Natl Cancer Inst; 2012 Feb; 104(3):228-39. PubMed ID: 22247021
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas.
Sasaki H; Shitara M; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Mol Med Rep; 2012 Mar; 5(3):599-602. PubMed ID: 22200795
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
40. Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer.
Tan DS; Haaland B; Gan JM; Tham SC; Sinha I; Tan EH; Lim KH; Takano A; Krisna SS; Thu MM; Liew HP; Ullrich A; Lim WT; Chua BT
Mol Cancer; 2014 Jan; 13():13. PubMed ID: 24461128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]